The complaint targets alleged violations of the Securities Exchange Act of 1934, specifically Sections 10(b) and 20(a). According to the legal filing, Capricor modified its statistical analysis framework for Deramiocel but proceeded with a Biologics License Application resubmission despite failing to reach an agreement with regulators regarding these changes. The DJS Law Group is currently representing investors affected by the subsequent market volatility.
Investors File Class Action Lawsuit Against Capricor Therapeutics
A new class action lawsuit alleges that Capricor Therapeutics misled shareholders by altering clinical trial statistical plans for its drug, Deramiocel, without prior FDA approval. The litigation, filed in federal court, centers on claims that the company disseminated false information between December 17, 2025, and July 26, 2026.
Shareholders who purchased CAPR stock during the designated class period face a September 28, 2026, deadline to seek appointment as lead plaintiff. David J. Schwartz of DJS Law Group notes that participation in the recovery process does not strictly require this lead designation. The firm, which specializes in securities litigation and corporate governance, is urging those who suffered financial losses to come forward to review their legal standing in the case.
Comments (0)
No comments yet. Be the first!